ImmunityBio
Tracked across 6 events · 112 articles · First seen Apr 01, 2026 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
ImmunityBio, Inc. is facing a securities class action lawsuit initiated by Kahn Swick & Foti, LLC, following a 21% decline in its stock price. The decline occurred after the United States — Food and Drug…
Impact: ImmunityBio is facing a securities class action lawsuit due to a significant drop in its stock price following a US Food and Drug Administration warning letter regarding misleading advertisements for its cancer therapy, Anktiva.
May 01, 2026 · 7 articles
Business
Rosen Law Firm has filed a securities class action lawsuit against ImmunityBio, a publicly traded company, on behalf of investors who purchased its securities between January 19, 2026, and March 24, 2026. The lawsuit alleges…
Impact: ImmunityBio is the defendant in a securities class action lawsuit, facing allegations of making false and misleading statements regarding Nogapendekin alfa inbakicept's capabilities, which could negatively impact its stock price and reputation.
May 01, 2026 · 6 articles
Regulatory
A class action lawsuit has been filed against ImmunityBio, Inc. and certain of its officers, including Defendant Soon-Shiong, by the investor-rights law firm Bronstein, Gewirtz & Grossman, LLC. The lawsuit alleges that ImmunityBio made materially…
Impact: ImmunityBio is the defendant in a class action lawsuit alleging that its officers made materially false and misleading statements regarding Nogapendekin alfa inbakicept's capabilities, leading to investor losses.
May 03, 2026 · 6 articles
Business
The Gross Law Firm has issued a notice to shareholders of ImmunityBio (NASDAQ: IBRX) regarding a class action lawsuit. The lawsuit alleges that during the period of January 19, 2026, to March 24, 2026, ImmunityBio…
Impact: ImmunityBio is the defendant in a class action lawsuit alleging that its statements about Anktiva's capabilities were materially false and misleading, which could negatively impact its stock price and reputation.
May 01, 2026 · 6 articles
Regulatory
ImmunityBio, a biotechnology company, is facing multiple securities class action lawsuits, initially filed by Rosen Law Firm and further investigated by Hagens Berman. The lawsuits allege that ImmunityBio and its executive chairman, Patrick Soon-Shiong, made…
Impact: ImmunityBio is facing a securities class action lawsuit for allegedly making misleading claims about its product Anktiva, which caused its stock price to drop and market capitalization to decrease by nearly $2 billion.
Apr 02, 2026 · 42 articles
100
ImmunityBio overstated capabilitiesImmunityBio Class Action...
100
Rosen Law Firm filed lawsuit ImmunityBioImmunityBio Faces Anktiva...
100
Rosen Law Firm filed lawsuit ImmunityBioImmunityBio Securities...
100
Bronstein, Gewirtz & Grossman, LLC filed lawsuit ImmunityBioImmunityBio faces Anktiva...
100
Bernstein Liebhard LLP filed lawsuit ImmunityBioImmunityBio Faces Anktiva...
95
United States — Food and Drug Administration sent warning letter ImmunityBioImmunityBio Faces Anktiva...
95
Kahn Swick & Foti filed class action lawsuit ImmunityBioImmunityBio FDA Warning, Stock Drop
95
Kessler Topaz Meltzer & Check filed lawsuit ImmunityBioImmunityBio Faces Anktiva...
90
United States — Food and Drug Administration issued warning letter ImmunityBioImmunityBio FDA Warning, Stock Drop
85
ImmunityBio overstated capabilitiesImmunityBio FDA Warning, Stock Drop
80
ImmunityBio stock price fellImmunityBio Faces Anktiva...
75
Hagens Berman investigated claims ImmunityBioImmunityBio Faces Anktiva...
Patrick Soon-Shiong
executive chairman
↔
ImmunityBio
Patrick Soon-Shiong serves as the Executive Chairman and Chief Scientific and Me
NEWSDESK
Track ImmunityBio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard